Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21819604 | 0.93 | ATF4 (0.55) | ATF4CNR1CNR2HTR7PAK4 | |
| SCHEMBL23920505 | 0.87 | ATF4 (0.56) | ATF4CNR1CNR2HTR7SCN9A | |
| SCHEMBL30053477 | 0.87 | ATF4 (0.55) | ATF4CNR1CNR2HTR7SCN9A | |
| SCHEMBL24997307 | 0.87 | ATF4 (0.55) | ATF4CNR1CNR2HTR7SCN9A | |
| SCHEMBL28584317 | 0.85 | ATF4 (0.54) | ATF4CNR1CNR2HTR7HRH3 | |
| SCHEMBL21819743 | 0.85 | ATF4 (0.63) | ATF4CNR1CNR2HTR7SCN9A | |
| SCHEMBL24997256 | 0.83 | ATF4 (0.52) | ATF4CNR1CNR2F10 | |
| SCHEMBL30054248 | 0.83 | ATF4 (0.52) | ATF4CNR1CNR2F10 | |
| SCHEMBL21882371 | 0.83 | ATF4 (0.53) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL28722608 | 0.83 | ATF4 (0.54) | ATF4CNR1CNR2HTR7SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | ATF4 1/4885CNR1 2950/4885CNR2 2686/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885CNR1 2950/4885CNR2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.